Inflammatory biomarkers and lipid metabolism parameters in women with mild cognitive impairment and dementia

References

• Alvarez, X. A., I. Alvarez, M. Aleixandre, C. Linares, D. Muresanu, S. Winter, and H. Moessler. 2018. Severity-related increase and cognitive correlates of serum VEGF levels in Alzheimer’s disease ApoE4 carriers. Journal of Alzheimer’s Disease 63 (3):1003–13. doi:10.3233/JAD-160477.
   PubMed Web of Science ®Google Scholar
• Amin, J., D. Erskine, P. C. Donaghy, A. Surendranathan, P. Swann, A. P. Kunicki, D. Boche, C. Holmes, I. G. McKeith, J. T. O’brien, et al. 2022. Inflammation in dementia with Lewy bodies. Neurobiology of Disease 168:105698. doi:10.1016/j.nbd.2022.105698.
   PubMed Web of Science ®Google Scholar
• Anstey, K. J., K. Ashby-Mitchell, and R. Peters. 2017. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: Review and meta-analysis. Journal of Alzheimer’s Disease 56 (1):215–28. doi:10.3233/JAD-160826.
   PubMed Web of Science ®Google Scholar
• Armstrong, R. A. 2013. What causes Alzheimer’s disease? Folia Neuropathological 51 (3):169–88. doi:10.5114/fn.2013.37702.
   PubMed Web of Science ®Google Scholar
• Björkqvist, M., M. Ohlsson, L. Minthon, and O. Hansson. 2012. Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer’s disease. PLoS One 7 (1):e29868. doi:10.1371/journal.pone.0029868.
   PubMed Web of Science ®Google Scholar
• Brosseron, F., M. Krauthausen, M. Kummer, and M. T. Heneka. 2014. Body fluid cytokine levels in mild cognitive impairment and Alzheimer’s disease: A comparative overview. Molecular Neurobiology 50 (2):534–44. doi:10.1007/s12035-014-8657-1.
   PubMed Web of Science ®Google Scholar
• Buchhave, P., H. Zetterberg, K. Blennow, L. Minthon, S. Janciauskiene, and O. Hansson. 2010. Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. Neurobiology of Aging 31 (11):1877–84. doi:10.1016/j.neurobiolaging.2008.10.012.
   PubMed Web of Science ®Google Scholar
• Creavin, S. T., S. Wisniewski, A. H. Noel-Storr, C. M. Trevelyan, T. Hampton, D. Rayment, V. M. Thom, K. J. Nash, H. Elhamoui, R. Milligan, et al. 2016. Mini-Mental State Examination (MMSE) for the detection of dementia in clinically unevaluated people aged 65 and over in community and primary care populations. Cochrane Database of Systematic Reviews 1:CD011145. doi:10.1002/14651858.CD011145.pub2.
   Google Scholar
• da Rocha, J. F., L. Bastos, S. C. Domingues, A. R. Bento, U. Konietzko, O. da Cruz E Silva, and S. I. Vieira. 2021. APP binds to the EGFR ligands HB-EGF and EGF, acting synergistically with EGF to promote ERK signaling and neuritogenesis. Molecular Neurobiology 58 (2):668–88. doi:10.1007/s12035-020-02139-2.
   PubMed Web of Science ®Google Scholar
• de Leeuw, F. A., W. M. van der Flier, B. M. Tijms, P. Scheltens, V. M. Mendes, B. Manadas, J. Bierau, N. van Wijk, E. van den Heuvel, M. H. Mohajeri, et al. 2020. Specific nutritional biomarker profiles in mild cognitive impairment and subjective cognitive decline are associated with clinical progression: The NUDAD project. Journal of the American Medical Directors Association 21 (10):1513.e1–1513.e17. doi:10.1016/j.jamda.2019.12.009.
   PubMed Web of Science ®Google Scholar
• Derreberry, T. M., and S. Holroyd. 2019. Dementia in women. The Medical Clinics of North America 103 (4):713–21. doi:10.1016/j.mcna.2019.02.004.
   PubMed Web of Science ®Google Scholar
• Desideri, G., F. Cipollone, S. Necozione, C. Marini, M. C. Lechiara, G. Taglieri, G. Zuliani, R. Fellin, A. Mezzetti, F. di Orio, et al. 2008. Enhanced soluble CD40 ligand and Alzheimer’s disease: Evidence of a possible pathogenetic role. Neurobiology of Aging 29 (3):348–56. doi:10.1016/j.neurobiolaging.2006.10.019.
   PubMed Web of Science ®Google Scholar
• Erol, R., D. Brooker, and E. Peel. 2015. Women and dementia: A global research review. London: Alzheimer’s Disease International. Accessed January 11, 2023. http://www.alz.co.uk/women-and-dementia.
   Google Scholar
• Erol, R., D. Brooker, and E. Peel. 2016. The impact of dementia on women internationally: An integrative review. Health Care for Women International 37 (12):1320–41. doi:10.1080/07399332.2016.1219357.
   PubMed Web of Science ®Google Scholar
• Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 18 (6):499–502. doi:10.1093/clinchem/18.6.499.
   PubMed Web of Science ®Google Scholar
• Giunta, B., K. Rezai-Zadeh, and J. Tan. 2010. Impact of the CD40-CD40L dyad in Alzheimer’s disease. CNS & Neurological Disorders Drug Targets 9 (2):149–55. doi:10.2174/187152710791012099.
   PubMed Web of Science ®Google Scholar
• He, Q., Q. Li, J. Zhao, T. Wu, L. Ji, G. Huang, and F. Ma. 2016. Relationship between plasma lipids and mild cognitive impairment in the elderly Chinese: A case-control study. Lipids in Health and Disease 15 (1):146. doi:10.1186/s12944-016-0320-6.
   PubMed Web of Science ®Google Scholar
• Heneka, M. T., M. J. Carson, J. El Khoury, G. E. Landreth, F. Brosseron, D. L. Feinstein, A. H. Jacobs, T. Wyss-Coray, J. Vitorica, R. M. Ransohoff, et al. 2015. Neuroinflammation in Alzheimer’s disease. Lancet Neurology 14 (4):388–405. doi:10.1016/S1474-4422(15)70016-5.
   PubMed Web of Science ®Google Scholar
• Ivanovska, M., Z. Abdi, M. Murdjeva, D. Macedo, A. Maes, and M. Maes. 2020. CCL-11 or eotaxin-1: An immune marker for ageing and accelerated ageing in neuro-psychiatric disorders. Pharmaceuticals (Basel, Switzerland) 13 (9):230. doi:10.3390/ph13090230.
   PubMedGoogle Scholar
• Kao, Y. C., P. C. Ho, Y. K. Tu, I. M. Jou, and K. J. Tsai. 2020. Lipids and Alzheimer’s disease. International Journal of Molecular Sciences 21 (4):1505. doi:10.3390/ijms21041505.
   PubMed Web of Science ®Google Scholar
• Karch, C. M., C. Cruchaga, and A. M. Goate. 2014. Alzheimer’s disease genetics: From the bench to the clinic. Neuron 83 (1):11–26. doi:10.1016/j.neuron.2014.05.041.
   PubMed Web of Science ®Google Scholar
• Kurmyshev, M. V., S. A. Zozulya, N. V. Zakharova, A. N. Barkhatova, I. Y. Nikiforova, and T. P. Klyushnik. 2022. Markers of systemic inflammation in assessing the effectiveness of neurocognitive rehabilitation in aged patients with mild cognitive impairment. Psikhiatriya 20 (3):47–56. doi:10.30629/2618-6667-2022-20-3-47-56.
   Google Scholar
• Lai, K., C. S. Liu, A. Rau, K. L. Lanctôt, C. A. Köhler, M. Pakosh, A. F. Carvalho, and N. Herrmann. 2017. Peripheral inflammatory markers in Alzheimer’s disease: A systematic review and meta-analysis of 175 studies. Journal of Neurology, Neurosurgery, and Psychiatry 88 (10):876–82. doi:10.1136/jnnp-2017-316201.
   PubMed Web of Science ®Google Scholar
• Lam, V., R. Takechi, M. M. Pallebage-Gamarallage, S. Galloway, and J. C. Mamo. 2011. Colocalisation of plasma derived apo B lipoproteins with cerebral proteoglycans in a transgenic-amyloid model of Alzheimer’s disease. Neuroscience Letters 492 (3):160–64. doi:10.1016/j.neulet.2011.02.001.
   PubMed Web of Science ®Google Scholar
• Lim, N. S., C. R. Swanson, H. R. Cherng, T. L. Unger, S. X. Xie, D. Weintraub, K. Marek, M. B. Stern, A. Siderowf, J. Q. Trojanowski, et al. 2016. Plasma EGF and cognitive decline in Parkinson’s disease and Alzheimer’s disease. Annals of Clinical and Translational Neurology 3 (5):346–55. doi:10.1002/acn3.299.
   PubMed Web of Science ®Google Scholar
• Liu, C., G. Cui, M. Zhu, X. Kang, and H. Guo. 2014. Neuroinflammation in Alzheimer’s disease: Chemokines produced by astrocytes and chemokine receptors. International Journal of Clinical and Experimental Pathology 7 (12):8342–55.
   PubMed Web of Science ®Google Scholar
• Liu, C., A. Liu, and S. Halabi. 2011. A min-max combination of biomarkers to improve diagnostic accuracy. Statistics in Medicine 30 (16):2005–14. doi:10.1002/sim.4238.
   PubMed Web of Science ®Google Scholar
• Liu, Y., X. Zhong, J. Shen, L. Jiao, J. Tong, W. Zhao, K. Du, S. Gong, M. Liu, and M. Wei. 2020. Elevated serum TC and LDL-C levels in Alzheimer’s disease and mild cognitive impairment: A meta-analysis study. Brain Research 1727:146554. doi:10.1016/j.brainres.2019.146554.
   PubMed Web of Science ®Google Scholar
• Loving, B. A., and K. D. Bruce. 2020. Lipid and lipoprotein metabolism in microglia. Frontiers in Physiology 11:393. doi:10.3389/fphys.2020.00393.
   PubMed Web of Science ®Google Scholar
• Meisner, A., C. R. Parikh, and K. F. Kerr. 2019. Biomarker combinations for diagnosis and prognosis in multicenter studies: Principles and methods. Statistical Methods in Medical Research 28 (4):969–85. doi:10.1177/0962280217740392.
   PubMed Web of Science ®Google Scholar
• Mendes-Santos, L. C., D. Mograbi, B. Spenciere, and H. Charchat-Fichman. 2015. Specific algorithm method of scoring the clock drawing test applied in cognitively normal elderly. Dementia & neuropsychologia 9 (2):128–35. doi:10.1590/1980-57642015DN92000007.
   PubMedGoogle Scholar
• Minter, M. R., J. M. Taylor, and P. J. Crack. 2016. The contribution of neuroinflammation to amyloid toxicity in Alzheimer’s disease. Journal of Neurochemistry 136 (3):457–74. doi:10.1111/jnc.13411.
   PubMed Web of Science ®Google Scholar
• Morgan, A. R., S. Touchard, C. Leckey, C. O’hagan, A. J. Nevado-Holgado, NIMA Consortium, F. Barkhof, L. Bertram, O. Blin, I. Bos, et al. 2019. Inflammatory biomarkers in Alzheimer’s disease plasma. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 15(6):776–87. doi:10.1016/j.jalz.2019.03.007.
   PubMed Web of Science ®Google Scholar
• Morozova, A., Y. Zorkina, K. Pavlov, O. Pavlova, O. Abramova, V. Ushakova, A. V. Mudrak, S. Zozulya, I. Otman, Z. Sarmanova, et al. 2021. Associations of genetic polymorphisms and neuroimmune markers with some parameters of frontal lobe dysfunction in schizophrenia. Frontiers in Psychiatry 12:655178. doi:10.3389/fpsyt.2021.655178.
   PubMed Web of Science ®Google Scholar
• Mukhara, D., U. Oh, and G. N. Neigh. 2020. Neuroinflammation. Handbook of Clinical Neurology 175:235–59. doi:10.1016/B978-0-444-64123-6.00017-5.
   PubMedGoogle Scholar
• Nasreddine, Z. S., N. A. Phillips, V. Bédirian, S. Charbonneau, V. Whitehead, I. Collin, J. L. Cummings, and H. Chertkow. 2005. The montreal cognitive assessment, MoCA: A brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society 53 (4):695–99. doi:10.1111/j.1532-5415.2005.53221.x.
   PubMed Web of Science ®Google Scholar
• Nebel, R. A., N. T. Aggarwal, L. L. Barnes, A. Gallagher, J. M. Goldstein, K. Kantarci, M. P. Mallampalli, E. C. Mormino, L. Scott, W. H. Yu, et al. 2018. Understanding the impact of sex and gender in Alzheimer’s disease: A call to action. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 14 (9):1171–83. doi:10.1016/j.jalz.2018.04.008.
   PubMed Web of Science ®Google Scholar
• Ohtani, R., S. Nirengi, M. Nakamura, N. Murase, M. Sainouchi, Y. Kuwata, M. Takata, Y. Masuda, K. Kotani, and N. Sakane. 2018. High-density lipoprotein subclasses and mild cognitive Impairment: Study of outcome and aPolipoproteins in dementia (STOP-dementia). Journal of Alzheimer’s Disease 66 (1):289–96. doi:10.3233/JAD-180135.
   PubMed Web of Science ®Google Scholar
• Park, J. C., S. H. Han, and I. Mook-Jung. 2020. Peripheral inflammatory biomarkers in Alzheimer’s disease: A brief review. BMB Reports 53 (1):10–19. doi:10.5483/BMBRep.2020.53.1.309.
   PubMed Web of Science ®Google Scholar
• Petersen, R. C. 2016. Mild Cognitive Impairment. Continuum (Minneapolis, Minn) 22 (2 Dementia):404–18. doi:10.1212/CON.0000000000000313.
   PubMedGoogle Scholar
• Pinto, T., L. Machado, T. M. Bulgacov, A. L. Rodrigues-Júnior, M. Costa, R. Ximenes, and E. B. Sougey. 2019. Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer’s Disease (AD) in the elderly? International Psychogeriatrics 31 (4):491–504. doi:10.1017/S1041610218001370.
   PubMed Web of Science ®Google Scholar
• Sanford, A. M. 2017. Mild cognitive impairment. Clinics in Geriatric Medicine 33 (3):325–37. doi:10.1016/j.cger.2017.02.005.
   PubMed Web of Science ®Google Scholar
• Scheyer, O., A. Rahman, H. Hristov, C. Berkowitz, R. S. Isaacson, R. Diaz Brinton, and L. Mosconi. 2018. Female sex and Alzheimer’s risk:The menopause connection. The Journal of Prevention of Alzheimer’s Disease 5 (4):225–30. doi:10.14283/jpad.2018.34.
   PubMed Web of Science ®Google Scholar
• Shen, X. N., Y. Lu, C. Tan, L. Y. Liu, J. T. Yu, L. Feng, and A. Larbi. 2019. Identification of inflammatory and vascular markers associated with mild cognitive impairment. Aging 11 (8):2403–19. doi:10.18632/aging.101924.
   PubMedGoogle Scholar
• Svensson, T., N. Sawada, M. Mimura, S. Nozaki, R. Shikimoto, and S. Tsugane. 2019. The association between midlife serum high-density lipoprotein and mild cognitive impairment and dementia after 19 years of follow-up. Translational Psychiatry 9 (1):26. doi:10.1038/s41398-018-0336-y.
   PubMed Web of Science ®Google Scholar
• Tahami Monfared, A. A., M. J. Byrnes, L. A. White, and Q. Zhang. 2022. The humanistic and economic burden of Alzheimer’s disease. Neurology and Therapy 11 (2):525–51. doi:10.1007/s40120-022-00335-x.
   PubMed Web of Science ®Google Scholar
• Tcw, J., L. Qian, N. H. Pipalia, M. J. Chao, S. A. Liang, Y. Shi, B. R. Jain, S. E. Bertelsen, M. Kapoor, E. Marcora, et al. 2022. Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. Cell 185 (13):2213–33.e25. doi:10.1016/j.cell.2022.05.017.
   PubMed Web of Science ®Google Scholar
• Teixeira, A. L., C. S. Gama, N. P. Rocha, and M. M. Teixeira. 2018. Revisiting the role of eotaxin-1/CCL11 in psychiatric disorders. Frontiers in Psychiatry 9:241. doi:10.3389/fpsyt.2018.00241.
   PubMed Web of Science ®Google Scholar
• Tian, Z., X. Ji, and J. Liu. 2022. Neuroinflammation in vascular cognitive impairment and dementia: Current evidence, advances, and prospects. International Journal of Molecular Sciences 23 (11):6224. doi:10.3390/ijms23116224.
   PubMed Web of Science ®Google Scholar
• Wimo, A., M. Guerchet, G. C. Ali, Y. T. Wu, A. M. Prina, B. Winblad, L. Jönsson, Z. Liu, and M. Prince. 2017. The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association 13 (1):1–7. doi:10.1016/j.jalz.2016.07.150.
   PubMed Web of Science ®Google Scholar
• Xu, T., Y. Fang, A. Rong, and J. Wang. 2015. Flexible combination of multiple diagnostic biomarkers to improve diagnostic accuracy. BMC Medical Research Methodology 15 (1):94. doi:10.1186/s12874-015-0085-z.
   PubMed Web of Science ®Google Scholar
• Yang, S. Y., C. L. Shan, H. Qing, W. Wang, Y. Zhu, M. M. Yin, S. Machado, T. F. Yuan, and T. Wu. 2015. The effects of aerobic exercise on cognitive function of Alzheimer’s disease patients. CNS & Neurological Disorders Drug Targets 14 (10):1292–97. doi:10.2174/1871527315666151111123319.
   PubMed Web of Science ®Google Scholar
• Yilmaz, C., K. Karali, G. Fodelianaki, A. Gravanis, T. Chavakis, I. Charalampopoulos, and V. I. Alexaki. 2019. Neurosteroids as regulators of neuroinflammation. Frontiers in Neuroendocrinology 55:100788. doi:10.1016/j.yfrne.2019.100788.
   PubMed Web of Science ®Google Scholar
• Yu, J. T., W. Xu, C. C. Tan, S. Andrieu, J. Suckling, E. Evangelou, A. Pan, C. Zhang, J. Jia, L. Feng, et al. 2020. Evidence-based prevention of Alzheimer’s disease: Systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. Journal of Neurology, Neurosurgery, and Psychiatry 91 (11):1201–09. doi:10.1136/jnnp-2019-321913.
   PubMed Web of Science ®Google Scholar
• Zuliani, G., A. Ble’, R. Zanca, M. R. Munari, A. Zurlo, C. Vavalle, A. R. Atti, and R. Fellin. 2001. Lipoprotein profile in older patients with vascular dementia and Alzheimer’s disease. BMC Geriatrics 1 (1):5. doi:10.1186/1471-2318-1-5.
   PubMedGoogle Scholar